133 related articles for article (PubMed ID: 18450736)
1. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
Xiao Z; Zhang Y; Li L; Nie L; Yang L; Xu S
Haematologica; 2008 May; 93(5):787-8. PubMed ID: 18450736
[No Abstract] [Full Text] [Related]
2. Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.
Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
J Int Med Res; 2009; 37(1):37-46. PubMed ID: 19215672
[TBL] [Abstract][Full Text] [Related]
3. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
5. [Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang].
Zhang XY; Maimaitili Y; Li Y; An L; Mao M; Fu L; Baier M; Wang XM
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1020-3. PubMed ID: 23363794
[TBL] [Abstract][Full Text] [Related]
6. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
[TBL] [Abstract][Full Text] [Related]
7. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
8. [The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].
Abdullaeva AO; Glinshchikova OA; Suslova SA; Shadieva NKh; Kolosova LIu; Meshcheriakova LM; Vakhrusheva MV; Sudarikov AB
Klin Lab Diagn; 2012 Jul; (7):24-8. PubMed ID: 22988798
[TBL] [Abstract][Full Text] [Related]
9. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
10. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
11. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
[TBL] [Abstract][Full Text] [Related]
12. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
14. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm.
Langabeer SE
J Clin Pathol; 2012 Dec; 65(12):1149-50. PubMed ID: 22872706
[No Abstract] [Full Text] [Related]
15. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
16. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.
Ohyashiki K; Aota Y; Akahane D; Gotoh A; Ohyashiki JH
Leukemia; 2007 May; 21(5):1097-9. PubMed ID: 17315023
[No Abstract] [Full Text] [Related]
17. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
[TBL] [Abstract][Full Text] [Related]
18. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
19. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.
Koh SP; Yip SP; Lee KK; Chan CC; Lau SM; Kho CS; Lau CK; Lin SY; Lau YM; Wong LG; Au KL; Wong KF; Chu RW; Yu PH; Chow EY; Leung KF; Tsoi WC; Yung BY
BMC Genet; 2014 Dec; 15():147. PubMed ID: 25526816
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.
Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M
Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
